2012;7:e48872
GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner
51,52 To address some of these limitations, a robust methodology was employed to identify potential confounders

CrossRef GLP1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, BoYeon Kim, Chang Won Jeong, DaeYeon Kim, Hang A Park, MinHo Kim, Seong Hwan Kim, WonWoo Seo, Woo Jin Kim, Young Sung Suh, Ra Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef GlucagonLike Peptide1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yongho Lee, Seng Chan You Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care Paola Mogna-Pelez, Marta Guasch-Ferr The Journal of Nutrition.2026

Our results are in line with previous findings showing the direct inhibitory effect of GSH on MMP-2 gelatinolytic capacity, and GSH-mediated increases in MMP-9 gelatinolytic activity in vitro (Bogani et al., 2007)
So the older "oral does nothing" framing has softened